NovaBay Pharmaceuticals, Inc. Stock

Equities

NBY

US66987P3001

Biotechnology & Medical Research

Market Closed - Nyse 16:00:00 2024-05-28 EDT 5-day change 1st Jan Change
0.141 USD +6.98% Intraday chart for NovaBay Pharmaceuticals, Inc. +7.31% -30.88%
Sales 2024 * 14.8M 20.21M Sales 2025 * 19.28M 26.34M Capitalization 5.08M 6.94M
Net income 2024 * -3M -4.1M Net income 2025 * - 0 EV / Sales 2024 * 0.34 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 0.26 x
P/E ratio 2024 *
-0.52 x
P/E ratio 2025 *
5.64 x
Employees 25
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.97%
More Fundamentals * Assessed data
Dynamic Chart
NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Earnings Flash (NBY) NOVABAY PHARMACEUTICALS Reports Q1 Revenue $2.63M, vs. Street Est of $3.28M MT
Transcript : NovaBay Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024
Transcript : NovaBay Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 26, 2024
NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (NBY) NOVABAY PHARMACEUTICALS Posts Q4 Revenue $3.7M, vs. Street Est of $3.4M MT
NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
New Age Investments LLC completed the acquisition of DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc.. CI
NovaBay Pharmaceuticals, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Fiscal Year 2023 CI
New Age Investments LLC entered into a Membership Unit Purchase Agreement to acquire DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc. for $1.07 million. CI
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals CI
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma?s Extensive Distributor Network CI
Transcript : NovaBay Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 09, 2023
NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (NBY) NOVABAY PHARMACEUTICALS Posts Q3 Revenue $3.3M, vs. Street Est of $3.55M MT
More news
1 day+6.98%
1 week+7.31%
Current month+74.50%
1 month+78.93%
3 months-8.50%
6 months-52.67%
Current year-30.88%
More quotes
1 week
0.13
Extreme 0.1287
0.15
1 month
0.08
Extreme 0.075
0.26
Current year
0.07
Extreme 0.065
0.26
1 year
0.07
Extreme 0.065
1.28
3 years
0.07
Extreme 0.065
30.70
5 years
0.07
Extreme 0.065
141.40
10 years
0.07
Extreme 0.065
1 137.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 46 13-01-31
Director of Finance/CFO 38 19-11-30
Members of the board TitleAgeSince
Chairman 89 02-04-30
Director/Board Member 67 19-09-10
Director/Board Member 49 16-01-25
More insiders
Date Price Change Volume
24-05-28 0.141 +6.98% 9,375,236
24-05-24 0.1318 -5.86% 9,768,666
24-05-23 0.14 +0.14% 12,733,563
24-05-22 0.1398 +6.39% 10,923,078
24-05-21 0.1314 -24.66% 20,243,372

Delayed Quote Nyse, May 28, 2024 at 04:00 pm

More quotes
NovaBay Pharmaceuticals, Inc. develops and sells scientifically created and clinically proven eyecare and wound care products. Its product, Avenova Antimicrobial Lid and Lash Solution, has antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. It offers a portfolio of products for each step of the standard at home treatment regimen, including the Avenova Eye Health Support antioxidant-rich oral supplement, Avenova Lubricating Eye Drops for instant relief, NovaWipes by Avenova, Avenova Warm Eye Compress to soothe the eyes, and the i-Chek by Avenova to monitor physical eyelid health. It also manufactures and sells its proprietary form of hypochlorous acid for the wound care market with its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers and other injuries.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.141 USD
Average target price
2.6 USD
Spread / Average Target
+1,743.97%
Consensus